Top

Published in:

01-04-2013 | Bladder and Urothelial Cancer (A Sagalowsky, Section Editor)

Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer

Authors: Timur Mitin, William U. Shipley, Jason A. Efstathiou, Niall M. Heney, Donald S. Kaufman, Richard J. Lee, Anthony L. Zietman

Published in: Current Urology Reports | Issue 2/2013

Abstract

During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. Epub 2003/08/29.PubMedCrossRef

Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011;186(4):1261–8. Epub 2011/08/19.PubMedCrossRef

Efstathiou JA, Quinn DI, Stenzl A, Bellmunt J, Cookson MS, Gakis G, et al. Radiation-based bladder preserving strategies: Radiation alone or combined with other modalities. In: Soloway MS, Khoury S, editors. Bladder Cancer: International Consultation on Bladder Cancer - Vienna, 2nd ed. Paris, France: Editions 21; 2012. p. 316-26.

•• Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705–11. Epub 2011/11/22. This is a long-term (7.7 years) followup of 348 patients treated with bladder-preservation trimodality therapy that allays fears of significant rates of late tumor recurrences and of poor bladder function. PubMedCrossRef

Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2013;63(1):45–57. doi:10.1016/j.eururo.2012.08.061.

Bladder Cancer. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf: National Comprehensive Cancer Network; 2012 [cited 2012 October 11]; Version 2.2012:[

Mak R, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-Term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Bladder- Preserving Combined-Modality Therapy: A Pooled Analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2012;30.

Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(11):2150–7. Epub 1993/11/01.

Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(1):119–26. Epub 1996/01/01.

10.

Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(14):3061–71. Epub 2002/07/16.CrossRef

11.

Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace 3rd HJ, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7. Epub 2008/12/23.PubMedCrossRef

12.

Shipley WU, Prout Jr GR, Kaufman SD, Perrone TL. Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. Cancer. 1987;60(3 Suppl):514–20. Epub 1987/08/01.PubMedCrossRef

13.

Dunst J, Sauer R, Schrott KM, Kuhn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys. 1994;30(2):261–6. Epub 1994/09/30.PubMedCrossRef

14.

Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(11):3576–83. Epub 1998/11/17.

15.

Onozawa M, Miyanaga N, Hinotsu S, Miyazaki J, Oikawa T, Kimura T, et al. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer. Jpn J Clin Oncol. 2012;42(9):825–30. Epub 2012/07/12.PubMedCrossRef

16.

•• James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88. Epub 2012/04/20. This is a randomized trial of radiation alone versus radiation with concurrent 5-FU/mitomycin C in patients with MIBC which establishes 5-FU/MMC as the alternative radiosensitization approach to cisplatin. PubMedCrossRef

17.

Efstathiou JA, Shipley WU. Re: Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. Eur Urol. 2013;63(1):181–2. doi:10.1056/NEJMoa1106106.

18.

• Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012;187(2):463–8. Epub 2011/12/20. This publication addresses concerns with salvage cystectomy for patients with disease persistence or recurrence after bladder-preservation treatment. PubMedCrossRef

19.

Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006;176(2):486–92. discussion 91-2. Epub 2006/07/04.PubMedCrossRef

20.

Novara G, De Marco V, Aragona M, Boscolo-Berto R, Cavalleri S, Artibani W, et al. Complications and mortality after radical cystectomy for bladder transitional cell cancer. J Urol. 2009;182(3):914–21. Epub 2009/07/21.PubMedCrossRef

21.

Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55(1):177–85. Epub 2008/07/22.PubMedCrossRef

22.

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(3):666–75. Epub 2001/02/07.

23.

Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(25):4055–61. Epub 2009/07/29.CrossRef

24.

Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170(5):1772–6. Epub 2003/10/09.PubMedCrossRef

25.

Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011;107(6):898–904. Epub 2011/01/20.PubMedCrossRef

26.

Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001;165(4):1111–6. Epub 2001/03/21.PubMedCrossRef

27.

• Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, et al. Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base. Eur Urol. 2012. This publication highlights the fact that curative modalities are greatly underutilized for elderly patients with MIBC in the United States. doi:10.1016/j.eururo.2012.11.015

28.

Muller AC, Diestelhorst A, Kuhnt T, Kuhn R, Fornara P, Scholz HJ, et al. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther Onkol: Organ Dtsch Rontgengesellschaft [et al]. 2007;183(4):177–83. Epub 2007/04/05.CrossRef

29.

Aravantinos. Proc Am Soc Clin Oncol. 2003;22.

30.

Foroudi F, Pham D, Bressel M, Wong J, Rolfo A, Roxby P, et al. Bladder cancer radiotherapy margins: a comparison of daily alignment using skin, bone or soft tissue. Clin Oncol (R Coll Radiol). 2012;24(10):673–81. doi:10.1016/j.clon.2012.06.012.

31.

Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62(2):309–17. Epub 2005/05/14.PubMedCrossRef

32.

Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer. 2002;102(5):514–8.PubMedCrossRef

33.

Jimenez RE, Hussain M, Bianco Jr FJ, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7(8):2440–7. Epub 2001/08/08.PubMed

34.

Choudhury A, Nelson LD, Teo MTW, Chilka S, Bhattarai S, Johnston CF, et al. MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer. Cancer Res. 2010;70(18):7017–26.PubMedCrossRef

35.

Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhoi BP, et al. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int. 2012;110(11):E1228–36. doi:10.1111/j.1464-410X.2012.11564.x.

Title: Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer
Authors: Timur Mitin
William U. Shipley
Jason A. Efstathiou
Niall M. Heney
Donald S. Kaufman
Richard J. Lee
Anthony L. Zietman
Publication date: 01-04-2013
Publisher: Current Science Inc.
Published in: Current Urology Reports / Issue 2/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-012-0301-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Practice Patterns in the Management of Urinary Lithiasis

The Role of Systemic Chemotherapy in Management of Upper Tract Urothelial Cancer

Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer

Evaluation of Renal Masses with Contrast-Enhanced Ultrasound

Advances in Tubeless Percutaneous Nephrolithotomy and Patient Selection: An Update

Contemporary Minimally Invasive Treatment Options for Renal Angiomyolipomas